Supernus Pharmaceuticals Inc (SUPN)

Exchange
NASDAQ
Symbol
SUPN
Sector
Life Sciences
Industry
Pharmaceutical Preparations
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of diseases of the central nervous system in the United States. The company is headquartered in Rockville, Maryland.
Country
USA

Stock price

At close: November 6, 2024

  • Open
    35.88
  • High
    38.21
  • Low
    35.33
  • Close
    37.75
  • Volume
    720,464

Financial ratios

Dec 31, 2023

Activity ratios
Inventory turnover
4.15
Receivables turnover
—
Payables turnover
—
Working capital turnover
2.98
Days of inventory on hand (DOH)
88.01
Days of sales outstanding (DSO)
—
Number of days of payables
—
Fixed asset turnover
605,106.00
Total asset turnover
605,106.00
 Liquidity ratios
Current ratio
1.70
Quick ratio
0.88
Cash ratio
0.88
Cash conversion cycle
88.01
 Solvency ratios
Debt-to-assets ratio
0.00
Debt-to-capital ratio
0.00
Debt-to-equity ratio
0.00
Financial leverage ratio
1.00
Interest coverage
4,194.00
 Profitability ratios
Gross profit margin
19.79%
Operating profit margin
-0.71%
Pretax margin
0.46%
Net profit margin
0.02%
Operating return on assets (Operating ROA)
-427,300.00%
Return on assets (ROA)
14,100.00%
Return on total capital
419,400.00%
Return on equity (ROE)
14,100.00%